Sanofi said it will pay MannKind as much as $925 million for the global rights to inhaled insulin Afrezza, just a couple months after the treatment received FDA approval. Afrezza is the world's only inhaled insulin, an alternative to injections for adults with diabetes. MannKind will receive an upfront payment of $150 million and milestone payments of up to $775 million, depending on the drug's commercial success. Sanofi and MannKind will share profits and losses on a global basis, with Sanofi retaining 65% and MannKind receiving 35%. Sanofi said the deal is the latest opportunity for the company to bring another insulin option to people with diabetes around the globe.

More from Video

60 Seconds: What is the Yield Curve and Why is Everyone Talking About It?

60 Seconds: What is the Yield Curve and Why is Everyone Talking About It?

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

Millennials Love Investing in Timeshares: Bluegreen Vacations CEO

Millennials Love Investing in Timeshares: Bluegreen Vacations CEO

60 Seconds: What's the Difference Between an ETF and a Mutual Fund?

60 Seconds: What's the Difference Between an ETF and a Mutual Fund?

Amazon's One-Year Anniversary of Buying Whole Foods: A Whole Lot of Silly Hype

Amazon's One-Year Anniversary of Buying Whole Foods: A Whole Lot of Silly Hype